Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus MIBELAS 24 FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus MIBELAS 24 FE.
ENSKYCE vs MIBELAS 24 FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination hormonal contraceptive: ethinyl estradiol suppresses LH and FSH, primarily inhibiting ovulation; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity, increasing cervical mucus viscosity and altering endometrial morphology.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet orally once daily for 24 days followed by 4 placebo tablets. Each tablet contains 75 mcg desogestrel and 0.02 mg ethinyl estradiol.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Drospirenone: ~30 hours; Ethinyl estradiol: ~17 hours. Steady-state reached after ~10 days for drospirenone.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Drospirenone: 40-50% renal as metabolites, <10% unchanged; ~50% fecal. Ethinyl estradiol: ~40% renal, 60% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive